Datopotamab deruxtecan
About
Therapy type: Targeted therapy
Therapy strategy: Topoisomerase inhibition, Trop-2 directed antibody
Mappings
NCI Thesaurus: Datopotamab Deruxtecan (ncit:C151967)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | EGFR somatic variants | Non-Small Cell Lung Cancer | Datopotamab deruxtecan | |
| FDA (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Datopotamab deruxtecan | |
| FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Datopotamab deruxtecan | |
| FDA (1) | EGFR p.T790M | Non-Small Cell Lung Cancer | Datopotamab deruxtecan | |
| FDA (1) | EGFR Exon 20 (Insertion) | Invasive Breast Carcinoma | Datopotamab deruxtecan | |
| FDA (1) | ER positive, HER2-negative | Invasive Breast Carcinoma | Datopotamab deruxtecan | |
| FDA (1) | HER2-negative, PR positive | Non-Small Cell Lung Cancer | Datopotamab deruxtecan | |
| FDA (1) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Datopotamab deruxtecan |